

# Filip K Knop

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3590468/filip-k-knop-publications-by-year.pdf>

**Version:** 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

426  
papers

12,720  
citations

57  
h-index

97  
g-index

496  
ext. papers

15,681  
ext. citations

5.3  
avg. IF

6.69  
L-index

#	Paper	IF	Citations
426	Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake.. <i>Obesity Surgery</i> , <b>2022</b> , 32, 1385	3.7	
425	FGF21 suppresses alcohol consumption through an amygdalo-striatal circuit.. <i>Cell Metabolism</i> , <b>2022</b> , 34, 317-328.e6	24.6	2
424	Glucose-dependent insulintropic polypeptide induces lipolysis during stable basal insulin substitution and hyperglycaemia in men with type 1 diabetes: A randomized, double-blind, placebo-controlled, crossover clinical trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2022</b> , 24, 142-147	6.7	0
423	Enterohepatic, Gluco-metabolic, and Gut Microbial Characterization of Individuals With Bile Acid Malabsorption <b>2022</b> , 1, 299-312		0
422	MYC mRNA expression throughout the intestine is not associated with body mass index or type 2 diabetes.. <i>Endocrinology, Diabetes and Metabolism</i> , <b>2022</b> , 5, e00327	2.7	1
421	LEAP2 reduces postprandial glucose excursions and food intake in healthy men.. <i>Cell Reports Medicine</i> , <b>2022</b> , 3, 100582	18	3
420	Hemoglobin A1c and Fructosamine Evaluated in Patients with Type 2 Diabetes Receiving Peritoneal Dialysis Using Long-Term Continuous Glucose Monitoring. <i>Nephron</i> , <b>2021</b> , 1-7	3.3	0
419	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes. <i>ELife</i> , <b>2021</b> , 10,	8.9	3
418	Prediabetes Defined by First Measured HbA Predicts Higher Cardiovascular Risk Compared With HbA in the Diabetes Range: A Cohort Study of Nationwide Registries. <i>Diabetes Care</i> , <b>2021</b> , 44, 2767-2774	14.6	0
417	The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma. <i>EBioMedicine</i> , <b>2021</b> , 73, 103661	8.8	4
416	INPP4B protects from metabolic syndrome and associated disorders. <i>Communications Biology</i> , <b>2021</b> , 4, 416	6.7	2
415	The role of GLP-1 in the postprandial effects of acarbose in type 2 diabetes. <i>European Journal of Endocrinology</i> , <b>2021</b> , 184, 383-394	6.5	6
414	Response to Letter to the Editor from McKee and McGill: "Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e4307-e4308	5.6	
413	Expression of Cholecystokinin and its Receptors in the Intestinal Tract of Type 2 Diabetes Patients and Healthy Controls. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 2164-2170	5.6	3
412	Prototype of an evidence-based tool to aid individualized treatment for type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 1666-1671	6.7	3
411	Pancreatic polypeptide: A potential biomarker of glucose-dependent insulintropic polypeptide receptor activation in vivo. <i>Diabetic Medicine</i> , <b>2021</b> , 38, e14592	3.5	0
410	A Pharmacological and Clinical Overview of Oral Semaglutide for the Treatment of Type 2 Diabetes. <i>Drugs</i> , <b>2021</b> , 81, 1003-1030	12.1	7

409	Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 343-353	6.5	2
408	Predictors of Improvement in Quality of Life When Treating Hypothyroidism. <i>Journal of Thyroid Research</i> , <b>2021</b> , 2021, 5577217	2.6	2
407	Azithromycin and hydroxychloroquine in hospitalised patients with confirmed COVID-19-a randomised double-blinded placebo-controlled trial. <i>European Respiratory Journal</i> , <b>2021</b> ,	13.6	11
406	Metabolic effects of 1-week binge drinking and fast food intake during Roskilde Festival in young healthy male adults. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 23-32	6.5	0
405	Effects of endogenous GIP in patients with type 2 diabetes. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, 33-45	6.5	4
404	Glycemic Control and Variability of Diabetes Secondary to Total Pancreatectomy Assessed by Continuous Glucose Monitoring. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, 168-173	5.6	6
403	Glycemic, maternal and neonatal outcomes in women with type 1 diabetes using continuous glucose monitoring during pregnancy - Pump vs multiple daily injections, a secondary analysis of an observational cohort study. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , <b>2021</b> , 100, 927-933	3.8	3
402	Reduced erythrocyte lifespan measured by chromium-51 in patients with type 2 diabetes undergoing long-term hemodialysis. <i>Hemodialysis International</i> , <b>2021</b> , 25, 198-204	1.7	
401	The Glycemic Effect of Liraglutide Evaluated by Continuous Glucose Monitoring in Persons with Type 2 Diabetes Receiving Dialysis. <i>Nephron</i> , <b>2021</b> , 145, 27-34	3.3	2
400	Identification and Metabolic Profiling of a Novel Human Gut-derived LEAP2 Fragment. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e966-e981	5.6	11
399	Dose-dependent efficacy of the glucose-dependent insulinotropic polypeptide (GIP) receptor antagonist GIP(3-30)NH on GIP actions in humans. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 68-74	6.7	8
398	Parenteral nutrition impairs plasma bile acid and gut hormone responses to mixed meal testing in lean healthy men. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 1013-1021	5.9	2
397	Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial. <i>American Journal of Clinical Nutrition</i> , <b>2021</b> , 113, 314-323	7	9
396	An overview of obesity mechanisms in humans: Endocrine regulation of food intake, eating behaviour and common determinants of body weight. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23 Suppl 1, 17-35	6.7	4
395	Protocol for a randomised, double-blinded, placebo-controlled, double-dummy 6-week clinical trial comparing the treatment effects of the glucagon-like peptide 1 receptor agonist liraglutide versus the bile acid sequestrant colesevelam on bile acid malabsorption. <i>BMJ Open</i> , <b>2021</b> , 11, e044711	3	0
394	Glucagonostatic Potency of GLP-1 in Patients With Type 2 Diabetes, Patients With Type 1 Diabetes, and Healthy Control Subjects. <i>Diabetes</i> , <b>2021</b> , 70, 1347-1356	0.9	2
393	How glucagon-like peptide 1 receptor agonists work. <i>Endocrine Connections</i> , <b>2021</b> , 10, R200-R212	3.5	4
392	The effect of 6-day subcutaneous glucose-dependent insulinotropic polypeptide infusion on time in glycaemic range in patients with type 1 diabetes: a randomised, double-blind, placebo-controlled crossover trial. <i>Diabetologia</i> , <b>2021</b> , 64, 2425-2431	10.3	0

391	Neurotensin secretion after Roux-en-Y gastric bypass, sleeve gastrectomy, and truncal vagotomy with pyloroplasty. <i>Neurogastroenterology and Motility</i> , <b>2021</b> , e14210	4	0
390	Exendin(9-39)NH : Recommendations for clinical use based on a systematic literature review. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23, 2419-2436	6.7	1
389	MECHANISMS IN ENDOCRINOLOGY: The physiology of neuronostatin. <i>European Journal of Endocrinology</i> , <b>2021</b> , 185, R93-R101	6.5	
388	Hepatic microbiome in healthy lean and obese humans. <i>JHEP Reports</i> , <b>2021</b> , 3, 100299	10.3	3
387	Treatment of type 2 diabetes in children: what are the specific considerations?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 2127-2141	4	0
386	Weight gain on antipsychotics - A perfect storm of complex pathophysiology and psychopharmacology. <i>Acta Psychiatrica Scandinavica</i> , <b>2021</b> , 144, 521-523	6.5	1
385	The Accuracy of Hemoglobin A1c and Fructosamine Evaluated by Long-Term Continuous Glucose Monitoring in Patients with Type 2 Diabetes Undergoing Hemodialysis. <i>Blood Purification</i> , <b>2021</b> , 1-9	3.1	
384	Understanding the place for GLP-1RA therapy: Translating guidelines for treatment of type 2 diabetes into everyday clinical practice and patient selection. <i>Diabetes, Obesity and Metabolism</i> , <b>2021</b> , 23 Suppl 3, 40-52	6.7	4
383	Study protocol for a multicentre, randomised, parallel group, sham-controlled clinical trial investigating the effect of transcutaneous vagal nerve stimulation on gastrointestinal symptoms in people with diabetes complicated with diabetic autonomic neuropathy: the DAN-VNS Study. <i>BMJ Open</i> , <b>2021</b> , 11, e038677	3	0
382	Associations of hypoglycemia, glycemic variability and risk of cardiac arrhythmias in insulin-treated patients with type 2 diabetes: a prospective, observational study.. <i>Cardiovascular Diabetology</i> , <b>2021</b> , 20, 241	8.7	3
381	High-Dose Glucagon Has Hemodynamic Effects Regardless of Cardiac Beta-Adrenoceptor Blockade: A Randomized Clinical Trial. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e016828	6	8
380	Gut Mucosal Gene Expression and Metabolic Changes After Roux-en-Y Gastric Bypass Surgery. <i>Obesity</i> , <b>2020</b> , 28, 2163-2174	8	2
379	Pregnancy loss is associated with type 2 diabetes: a nationwide case-control study. <i>Diabetologia</i> , <b>2020</b> , 63, 1521-1529	10.3	9
378	The GLP-1 receptor agonist lixisenatide reduces postprandial glucose in patients with diabetes secondary to total pancreatectomy: a randomised, placebo-controlled, double-blinded crossover trial. <i>Diabetologia</i> , <b>2020</b> , 63, 1285-1298	10.3	2
377	The effect of acute intragastric vs. intravenous alcohol administration on inflammation markers, blood lipids and gallbladder motility in healthy men. <i>Alcohol</i> , <b>2020</b> , 87, 29-37	2.7	1
376	Differential time responses in inflammatory and oxidative stress markers after a marathon: An observational study. <i>Journal of Sports Sciences</i> , <b>2020</b> , 38, 2080-2091	3.6	11
375	Proactive Prophylaxis With Azithromycin and HydroxyChloroquine in Hospitalised Patients With COVID-19 (ProPAC-COVID): A structured summary of a study protocol for a randomised controlled trial. <i>Trials</i> , <b>2020</b> , 21, 513	2.8	9
374	Hypoglycaemia and cardiac arrhythmias in diabetes. <i>Therapeutic Advances in Endocrinology and Metabolism</i> , <b>2020</b> , 11, 2042018820911803	4.5	12

373	Effect of short-acting exenatide administered three times daily on markers of cardiovascular disease in type 1 diabetes: A randomized double-blind placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1639-1647	6.7	1
372	GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1 $\beta$ Mutation Carriers. <i>Diabetes</i> , <b>2020</b> , 69, 1989-2002	0.9	7
371	Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2020</b> , 8, 313-324	18.1	18
370	Human translatability of the GAN diet-induced obese mouse model of non-alcoholic steatohepatitis. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 210	3	9
369	What is on the horizon for type 2 diabetes pharmacotherapy? - An overview of the antidiabetic drug development pipeline. <i>Expert Opinion on Drug Discovery</i> , <b>2020</b> , 15, 1253-1265	6.2	4
368	Clinical pharmacology of imeglimin for the treatment of type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 871-882	4	6
367	L-Cell Differentiation Is Induced by Bile Acids Through GPBAR1 and Paracrine GLP-1 and Serotonin Signaling. <i>Diabetes</i> , <b>2020</b> , 69, 614-623	0.9	24
366	GIP and GLP-1 Receptor Antagonism During a Meal in Healthy Individuals. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	18
365	No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes. <i>Diabetes Care</i> , <b>2020</b> , 43, 588-596	14.6	18
364	Glucagon Resistance at the Level of Amino Acid Turnover in Obese Subjects With Hepatic Steatosis. <i>Diabetes</i> , <b>2020</b> , 69, 1090-1099	0.9	15
363	Use of inhaled corticosteroids and the risk of developing type 2 diabetes in patients with chronic obstructive pulmonary disease. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 1348-1356	6.7	9
362	Secretion of parathyroid hormone may be coupled to insulin secretion in humans. <i>Endocrine Connections</i> , <b>2020</b> , 9, 747-754	3.5	1
361	10-LB: Dasiglucagon Ameliorates Postprandial Hypoglycemia after Roux-en-y Gastric Bypass. <i>Diabetes</i> , <b>2020</b> , 69, 10-LB	0.9	3
360	89-LB: The Effect of GIP on Plasma Glucose in a Setting of Prandial Insulin Overdose and Physical Activity after Meal Intake in Patients with Type 1 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 89-LB	0.9	2
359	2187-PUB: Identifying Risk Predictors for Gastrointestinal Adverse Events with Once-Weekly Semaglutide. <i>Diabetes</i> , <b>2020</b> , 69, 2187-PUB	0.9	
358	1906-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients with Type 2 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 1906-P	0.9	
357	160-OR: Acute Changes in Plasma Glucose Have Impact on Left Ventricular Systolic Function in Insulin-Treated Patients with Type 2 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 160-OR	0.9	
356	263-OR: Counterregulatory Responses to Hypoglycemia in Totally Pancreatectomized Patients. <i>Diabetes</i> , <b>2020</b> , 69, 263-OR	0.9	

355	923-P: Improved Glycemic Variability and Control without Increased Risk of Hypoglycemia when Linagliptin Is Added to Glimepiride Therapy in Patients with HNF1A-Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 923-P	0.9	
354	1140-P: Empagliflozin Attenuates Fasting and Postprandial Hyperglycemia in Totally Pancreatectomized Patients: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. <i>Diabetes</i> , <b>2020</b> , 69, 1140-P	0.9	
353	1662-P: Lower Expression of Bile Acid Transporters and Fibroblast Growth Factor 19 in Mucosa Biopsies from the Ileocecal Region in Persons with Type 2 Diabetes Compared with Healthy Controls. <i>Diabetes</i> , <b>2020</b> , 69, 1662-P	0.9	
352	2160-PUB: Development of an Evidence-Based Tool to Facilitate Individualized Treatment in the Clinic for Patients with Type 2 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 2160-PUB	0.9	
351	1052-P: Investigation of the Extrapancreatic Effects of the DPP-4 Inhibitor Sitagliptin: A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial in Totally Pancreatectomized Patients. <i>Diabetes</i> , <b>2020</b> , 69, 1052-P	0.9	
350	1905-P: Downregulation of HMGCS2 Expression in Small Intestinal Mucosa Biopsies after Roux-en-Y Gastric Bypass Surgery: A Possible Contributor to GLP-1 Hypersecretion?. <i>Diabetes</i> , <b>2020</b> , 69, 1905-P	0.9	
349	351-OR: Six-Day Subcutaneous GIP Infusion Increases Glycemic Time-in-Range in Patients with Type 1 Diabetes. <i>Diabetes</i> , <b>2020</b> , 69, 351-OR	0.9	0
348	2103-P: Glucose-Dependent Insulinotropic Polypeptide (GIP) Protects against Cytokine-Induced Cell Death and Exerts Both Insulinotropic and Glucagonotropic Effects in Human Islets. <i>Diabetes</i> , <b>2020</b> , 69, 2103-P	0.9	
347	1094-P: Short-Acting Exenatide and Markers of Cardiovascular Disease in Type 1 Diabetes: A Randomized, Double-Blinded, Placebo-Controlled Trial. <i>Diabetes</i> , <b>2020</b> , 69, 1094-P	0.9	
346	No detectable effect of a type 2 diabetes-associated TCF7L2 genotype on the incretin effect. <i>Endocrine Connections</i> , <b>2020</b> , 9, 1221-1232	3.5	2
345	Glucagon-Like Peptide 2 Inhibits Postprandial Gallbladder Emptying in Man: A Randomized, Double-Blinded, Crossover Study. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00257	4.2	1
344	GIP(3-30)NH - a tool for the study of GIP physiology. <i>Current Opinion in Pharmacology</i> , <b>2020</b> , 55, 31-40	5.1	1
343	Myocardial Impairment and Acute Respiratory Distress Syndrome in Hospitalized Patients With COVID-19: The ECHOVID-19 Study. <i>JACC: Cardiovascular Imaging</i> , <b>2020</b> , 13, 2474-2476	8.4	5
342	GIP and the gut-bone axis - Physiological, pathophysiological and potential therapeutic implications. <i>Peptides</i> , <b>2020</b> , 125, 170197	3.8	11
341	Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. <i>Peptides</i> , <b>2020</b> , 125, 170183	3.8	21
340	Human myotubularin-related protein 9 regulates ER-to-Golgi trafficking and modulates WNT3A secretion. <i>Experimental Cell Research</i> , <b>2020</b> , 386, 111709	4.2	0
339	Experience of family function, family involvement, and self-management in adult patients with type 2 diabetes: A thematic analysis. <i>Journal of Advanced Nursing</i> , <b>2020</b> , 76, 621-631	3.1	3
338	GIP involvement in the pathophysiology of type 2 diabetes. <i>Peptides</i> , <b>2020</b> , 125, 170178	3.8	7

337	Glucose-Dependent Insulinotropic Polypeptide Is a Pancreatic Polypeptide Secretagogue in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	2
336	GIP effect on bone metabolism is reduced by the selective GIP receptor antagonist GIP(3-30)NH <sub>2</sub> . <i>Bone</i> , <b>2020</b> , 130, 115079	4.7	11
335	Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease. <i>Peptides</i> , <b>2020</b> , 125, 170174	3.8	12
334	The Role of Glucagon in the Acute Therapeutic Effects of SGLT2 Inhibition. <i>Diabetes</i> , <b>2020</b> , 69, 2619-2629.	9.9	5
333	Circulating Levels of the Soluble Receptor for AGE (sRAGE) during Escalating Oral Glucose Dosages and Corresponding Isoglycaemic i.v. Glucose Infusions in Individuals with and without Type 2 Diabetes. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	1
332	Antidiabetes Agents and Incident Depression: A Nationwide Population-Based Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 3050-3060	14.6	11
331	Glucagon acutely regulates hepatic amino acid catabolism and the effect may be disturbed by steatosis. <i>Molecular Metabolism</i> , <b>2020</b> , 42, 101080	8.8	16
330	One Year Treatment with the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide Decreases Hepatic Fat Content in Women with Nonalcoholic Fatty Liver Disease and Prior Gestational Diabetes Mellitus in a Randomized, Placebo-Controlled Trial. <i>Journal of Clinical Medicine</i> , <b>2020</b> , 9,	5.1	2
329	Normal insulin sensitivity, glucose tolerance, gut incretin and pancreatic hormone responses in adults with atopic dermatitis. <i>Diabetes, Obesity and Metabolism</i> , <b>2020</b> , 22, 2161-2169	6.7	0
328	Influenza Vaccination Is Associated With Reduced Cardiovascular Mortality in Adults With Diabetes: A Nationwide Cohort Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 2226-2233	14.6	9
327	Efficacy and Safety of Glimepiride With or Without Linagliptin Treatment in Patients With HNF1A Diabetes (Maturity-Onset Diabetes of the Young Type 3): A Randomized, Double-Blinded, Placebo-Controlled, Crossover Trial (GLIMLINA). <i>Diabetes Care</i> , <b>2020</b> , 43, 2025-2033	14.6	10
326	The role of endogenous GIP and GLP-1 in postprandial bone homeostasis. <i>Bone</i> , <b>2020</b> , 140, 115553	4.7	10
325	Glucose-Dependent Insulinotropic Polypeptide (GIP) Reduces Bone Resorption in Patients With Type 2 Diabetes. <i>Journal of the Endocrine Society</i> , <b>2020</b> , 4, bvaa097	0.4	3
324	Echocardiographic abnormalities and predictors of mortality in hospitalized COVID-19 patients: the ECHOVID-19 study. <i>ESC Heart Failure</i> , <b>2020</b> , 7, 4189	3.7	39
323	Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. <i>Trials</i> , <b>2020</b> , 21, 867	2.8	5
322	Changes in oxidative nucleic acid modifications and inflammation following one-week treatment with the bile acid sequestrant sevelamer: Two randomised, placebo-controlled trials. <i>Journal of Diabetes and Its Complications</i> , <b>2020</b> , 34, 107446	3.2	3
321	Glucose-Metabolic Effects of Pharmacotherapy-Induced Modulation of Bile Acid Physiology. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2020</b> , 105,	5.6	5
320	Amylin and Calcitonin: Potential Therapeutic Strategies to Reduce Body Weight and Liver Fat. <i>Frontiers in Endocrinology</i> , <b>2020</b> , 11, 617400	5.7	15

319	O12.4. EFFECTS OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST EXENATIDE ON BONE STATUS IN OBESE, NON-DIABETIC, ANTIPSYCHOTIC-TREATED SCHIZOPHRENIA SPECTRUM PATIENTS. <i>Schizophrenia Bulletin</i> , <b>2019</b> , 45, S198-S199	1.3	1
318	The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion-A Review. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	23
317	Metabolic profile in patients with newly diagnosed bipolar disorder and their unaffected first-degree relatives. <i>International Journal of Bipolar Disorders</i> , <b>2019</b> , 7, 8	5.4	21
316	Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study. <i>Diabetologia</i> , <b>2019</b> , 62, 665-675	10.3	51
315	Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 242	5.7	4
314	Effect of liraglutide on body weight and pain in patients with overweight and knee osteoarthritis: protocol for a randomised, double-blind, placebo-controlled, parallel-group, single-centre trial. <i>BMJ Open</i> , <b>2019</b> , 9, e024065	3	3
313	Clinical characteristics and glucose-lowering drug utilization among patients initiating liraglutide in Denmark: a routine clinical care prescription study. <i>Journal of Diabetes</i> , <b>2019</b> , 11, 690-694	3.8	3
312	Plasma proteome profiling discovers novel proteins associated with non-alcoholic fatty liver disease. <i>Molecular Systems Biology</i> , <b>2019</b> , 15, e8793	12.2	94
311	Bariatric surgery in patients with non-alcoholic fatty liver disease - from pathophysiology to clinical effects. <i>World Journal of Hepatology</i> , <b>2019</b> , 11, 138-149	3.4	75
310	Continuous glucose monitoring in pregnant women with type 1 diabetes: an observational cohort study of 186 pregnancies. <i>Diabetologia</i> , <b>2019</b> , 62, 1143-1153	10.3	54
309	Separate and Combined Effects of GIP and GLP-1 Infusions on Bone Metabolism in Overweight Men Without Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2953-2960	5.6	26
308	Association Between Topical Corticosteroid Use and Type 2 Diabetes in Two European Population-Based Adult Cohorts. <i>Diabetes Care</i> , <b>2019</b> , 42, 1095-1103	14.6	17
307	Glucagon Receptor Signaling and Lipid Metabolism. <i>Frontiers in Physiology</i> , <b>2019</b> , 10, 413	4.6	44
306	The efficacy and safety of exenatide once weekly in patients with type 2 diabetes. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 501-510	4	9
305	Extrapancreatic glucagon: Present status. <i>Diabetes Research and Clinical Practice</i> , <b>2019</b> , 147, 19-28	7.4	7
304	New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 2463-2472	5.6	10
303	Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion. <i>Liver International</i> , <b>2019</b> , 39, 2094-2101	7.9	23
302	Investigating Intestinal Glucagon After Roux-en-Y Gastric Bypass Surgery. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> , 104, 6403-6416	5.6	21



301	Glucagon Receptor Signaling and Glucagon Resistance. <i>International Journal of Molecular Sciences</i> , <b>2019</b> , 20,	6.3	46
300	The Liver-Cell Axis and Type 2 Diabetes. <i>Endocrine Reviews</i> , <b>2019</b> , 40, 1353-1366	27.2	53
299	Remission of Bile Acid Malabsorption Symptoms Following Treatment With the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Gastroenterology</i> , <b>2019</b> , 157, 569-571	13.3	4
298	Glucocorticoid effects of oral and intravenous alcohol administration in men. <i>Endocrine Connections</i> , <b>2019</b> , 8, 1372-1382	3.5	4
297	A role for exogenous GLP-1 in the management of postprandial hypoglycaemia after Roux-en-Y gastric bypass?. <i>European Journal of Endocrinology</i> , <b>2019</b> , 181, C5-C8	6.5	2
296	1145-P: Acarbose-Induced Glucagon-Like Peptide-1 Secretion Contributes to the Glucose-Lowering Effect of Acarbose. <i>Diabetes</i> , <b>2019</b> , 68, 1145-P	0.9	2
295	1952-P: Glucagon Receptor Antagonism Increases Plasma Amino Acids and Glucagon. <i>Diabetes</i> , <b>2019</b> , 68, 1952-P	0.9	1
294	1976-P: Physiological Effects of GIP(1-30)NH <sub>2</sub> in Healthy Subjects. <i>Diabetes</i> , <b>2019</b> , 68, 1976-P	0.9	1
293	64-OR: Postprandial Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide in Type 2 Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 64-OR	0.9	10
292	981-P: GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in HNF1A Diabetes. <i>Diabetes</i> , <b>2019</b> , 68, 981-P	0.9	1
291	1980-P: A Characterization of Postprandial Glucose Metabolism and Incretin Hormone Responses in Patients with Bile Acid Malabsorption. <i>Diabetes</i> , <b>2019</b> , 68, 1980-P	0.9	
290	1186-P: Lean Women with Polycystic Ovary Syndrome and Insulin Resistance Have Normal Incretin Effect, which is Unaffected by Metformin Therapy. <i>Diabetes</i> , <b>2019</b> , 68, 1186-P	0.9	
289	62-OR: Evidence of Gut-Derived Glucagon in Man. <i>Diabetes</i> , <b>2019</b> , 68, 62-OR	0.9	
288	63-OR: The Physiological Effects of Extraprostatic Glucagon in Totally Pancreatectomized Patients Evaluated Using Glucagon Receptor Antagonism. <i>Diabetes</i> , <b>2019</b> , 68, 63-OR	0.9	
287	23-OR: The Effect of 14-Day Atorvastatin Treatment on Postprandial Glucose Metabolism in Healthy Males: A Link to Why Statin Therapy Increases the Risk of Type 2 Diabetes?. <i>Diabetes</i> , <b>2019</b> , 68, 23-OR	0.9	
286	1982-P: Glucagon-Like Peptide-2 Inhibits Postprandial Gallbladder Emptying in Healthy Male Individuals: A Randomized, Double-Blinded, Placebo-Controlled Study. <i>Diabetes</i> , <b>2019</b> , 68, 1982-P	0.9	
285	-acyl taurines are endogenous lipid messengers that improve glucose homeostasis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2019</b> , 116, 24770-24778	11.5	10
284	Gastrin secretion in normal subjects and diabetes patients is inhibited by glucagon-like peptide 1: a role in the gastric side effects of GLP-1-derived drugs?. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1448-1451	2.4	5

283	Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 293-302	6.7	40
282	Management of people with Type 2 diabetes shared between a specialized outpatient clinic and primary health care is noninferior to management in a specialized outpatient clinic: a randomized, noninferiority trial. <i>Diabetic Medicine</i> , <b>2019</b> , 36, 854-861	3.5	3
281	Hepatic transcriptome signatures in patients with varying degrees of nonalcoholic fatty liver disease compared with healthy normal-weight individuals. <i>American Journal of Physiology - Renal Physiology</i> , <b>2019</b> , 316, G462-G472	5.1	63
280	Separate and Combined Glucometabolic Effects of Endogenous Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide 1 in Healthy Individuals. <i>Diabetes</i> , <b>2019</b> , 68, 906-917	0.9	70
279	Glucose metabolism in patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2019</b> , 180, 264-271	4	7
278	Patient Assessment of Family Function, Glycemic Control and Quality of Life in Adult Patients With Type 2 Diabetes and Incipient Complications. <i>Canadian Journal of Diabetes</i> , <b>2019</b> , 43, 193-200	2.1	8
277	Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density. <i>Frontiers in Psychiatry</i> , <b>2018</b> , 9, 781	5	7
276	Glucose-lowering effects and mechanisms of the bile acid-sequestering resin sevelamer. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1623-1631	6.7	11
275	Duodenal L cell density correlates with features of metabolic syndrome and plasma metabolites. <i>Endocrine Connections</i> , <b>2018</b> , 7, 673-680	3.5	1
274	EJE PRIZE 2018: A gut feeling about glucagon. <i>European Journal of Endocrinology</i> , <b>2018</b> , 178, R267-R280	6.5	23
273	Is glucagon-like peptide-1 fully protected by the dipeptidyl peptidase 4 inhibitor sitagliptin when administered to patients with type 2 diabetes?. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1937-1943	6.7	3
272	FGF21, a liver hormone that inhibits alcohol intake in mice, increases in human circulation after acute alcohol ingestion and sustained binge drinking at Oktoberfest. <i>Molecular Metabolism</i> , <b>2018</b> , 11, 96-103	8.8	34
271	Ghrelin secretion in humans - a role for the vagus nerve?. <i>Neurogastroenterology and Motility</i> , <b>2018</b> , 30, e13295	4	13
270	Glucose-Dependent Insulinotropic Polypeptide (GIP) Inhibits Bone Resorption Independently of Insulin and Glycemia. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 288-294	5.6	46
269	Cardiovascular biomarkers in clinical studies of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 1350-1360	6.7	13
268	Glucose-dependent insulinotropic polypeptide (GIP) receptor antagonists as anti-diabetic agents. <i>Peptides</i> , <b>2018</b> , 100, 173-181	3.8	44
267	Evidence of a liver-alpha cell axis in humans: hepatic insulin resistance attenuates relationship between fasting plasma glucagon and glucagonotropic amino acids. <i>Diabetologia</i> , <b>2018</b> , 61, 671-680	10.3	41
266	The Role of Glucagon in the Pathophysiology and Treatment of Type 2 Diabetes. <i>Mayo Clinic Proceedings</i> , <b>2018</b> , 93, 217-239	6.4	57

265	Guanylin and uroguanylin mRNA expression is increased following Roux-en-Y gastric bypass, but guanylins do not play a significant role in body weight regulation and glycemic control. <i>Peptides</i> , <b>2018</b> , 101, 32-43	3.8	9
264	Glucagon-like peptide 1 in health and disease. <i>Nature Reviews Endocrinology</i> , <b>2018</b> , 14, 390-403	15.2	187
263	Effects of Smoking Versus Nonsmoking on Postprandial Glucose Metabolism in Heavy Smokers Compared With Nonsmokers. <i>Diabetes Care</i> , <b>2018</b> , 41, 1260-1267	14.6	7
262	GIP(3-30)NH is an efficacious GIP receptor antagonist in humans: a randomised, double-blinded, placebo-controlled, crossover study. <i>Diabetologia</i> , <b>2018</b> , 61, 413-423	10.3	52
261	Effects of glucagon-like peptide-1 receptor agonists on cardiovascular risk factors: A narrative review of head-to-head comparisons. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 508-519	6.7	25
260	Hyperglucagonemia correlates with plasma levels of non-branched-chain amino acids in patients with liver disease independent of type 2 diabetes. <i>American Journal of Physiology - Renal Physiology</i> , <b>2018</b> , 314, G91-G96	5.1	29
259	Enteroendocrine K and L cells in healthy and type 2 diabetic individuals. <i>Diabetologia</i> , <b>2018</b> , 61, 284-294	10.3	66
258	Protocol for Meal-time Administration of Exenatide for Glycaemic Control in Type 1 Diabetes Cases (The MAG1C trial): a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , <b>2018</b> , 8, e021861	3	2
257	Differences Between Randomized Clinical Trial Patients and Real-World Initiators of the Glucagon-Like Peptide 1 Receptor Agonist Liraglutide. <i>Diabetes Care</i> , <b>2018</b> , 41, e133-e135	14.6	12
256	Hemodynamic Effects of Glucagon: A Literature Review. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 1804-1812	5.6	17
255	Restoration of enteroendocrine and pancreatic function after internal hernia and short bowel syndrome in a young woman with gastric bypass - a 2-year follow-up. <i>Physiological Reports</i> , <b>2018</b> , 6, e13688	2.6	1
254	Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2018</b> , 7, 603-612	4.5	9
253	Effects of liraglutide on gallbladder emptying: A randomized, placebo-controlled trial in adults with overweight or obesity. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 2557-2564	6.7	15
252	Metformin-induced glucagon-like peptide-1 secretion contributes to the actions of metformin in type 2 diabetes. <i>JCI Insight</i> , <b>2018</b> , 3,	9.9	44
251	Postprandial Effects of Individual and Combined GIP and GLP-1 Receptor Antagonization in Healthy Subjects. <i>Diabetes</i> , <b>2018</b> , 67, 145-OR	0.9	2
250	Glucagon Resistance at the Level of Amino Acid Turnover and Ureagenesis in Obese Subjects with Hepatic Steatosis. <i>Diabetes</i> , <b>2018</b> , 67, 147-OR	0.9	1
249	Mono- and Co-Activation of the GIP and GLP-1 Receptors Inhibits Bone Resorption. <i>Diabetes</i> , <b>2018</b> , 67, 1939-P	0.9	3
248	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Sodium-Glucose Cotransporter 2 Inhibition. <i>Diabetes</i> , <b>2018</b> , 67, 1942-P	0.9	1

247	Individual and Combined Glucose-Lowering Effects of Glucagon Receptor Antagonism and Dipeptidyl Peptidase-4 Inhibition. <i>Diabetes</i> , <b>2018</b> , 67, 274-LB	0.9	0
246	The Effect of Ethanol on Inflammation Markers and FGF-21 in Healthy Individuals. <i>Diabetes</i> , <b>2018</b> , 67, 2415-PUB	0.9	
245	Clinical Features and Hepatic Molecular Characteristics in NAFLD and NASH Patients Compared to Normal Weight Healthy Individuals. <i>Diabetes</i> , <b>2018</b> , 67, 260-LB	0.9	1
244	More Subjects Achieved Composite Reductions of =1% HbA1c, =5% Body Weight, and =5 mmHg SBP with Semaglutide vs. Comparators (SUSTAIN 1-5, 7). <i>Diabetes</i> , <b>2018</b> , 67, 129-OR	0.9	
243	Glucagon-Like Peptide-1 Is a Significant Determinant of the Second-Meal Effect in Patients with Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 1963-P	0.9	
242	The Role of Glucagon-Like Peptide-1 for the Postprandial Effects of Metformin in Type 2 Diabetes. <i>Diabetes</i> , <b>2018</b> , 67, 1969-P	0.9	
241	Management of Patients with Type 2 Diabetes Shared between a Specialized Outpatient Clinic and General Practice Was Noninferior to Mono Management in a Specialized Outpatient Clinic: A Prospective, Randomized, Noninferiority Trial. <i>Diabetes</i> , <b>2018</b> , 67, 6-OR	0.9	
240	The bile acid-sequestering resin sevelamer eliminates the acute GLP-1 stimulatory effect of endogenously released bile acids in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 362-369	6.7	26
239	Future Perspectives on GLP-1 Receptor Agonists and GLP-1/glucagon Receptor Co-agonists in the Treatment of NAFLD. <i>Frontiers in Endocrinology</i> , <b>2018</b> , 9, 649	5.7	43
238	Cholecystokinin secretion is suppressed by glucagon-like peptide-1: clue to the mechanism of the adverse gallbladder events of GLP-1-derived drugs. <i>Scandinavian Journal of Gastroenterology</i> , <b>2018</b> , 53, 1429-1432	2.4	9
237	Comparing olive oil and C4-dietary oil, a prodrug for the GPR119 agonist, 2-oleoyl glycerol, less energy intake of the latter is needed to stimulate incretin hormone secretion in overweight subjects with type 2 diabetes. <i>Nutrition and Diabetes</i> , <b>2018</b> , 8, 2	4.7	7
236	Glimepiride monotherapy versus combination of glimepiride and linagliptin therapy in patients with HNF1A-diabetes: a protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , <b>2018</b> , 8, e022517	3	5
235	Response to Letter to the Editor: "Hemodynamic Effects of Glucagon: A Literature Review". <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 4480-4481	5.6	
234	Determinants of Fasting Hyperglucagonemia in Patients with Type 2 Diabetes and Nondiabetic Control Subjects. <i>Metabolic Syndrome and Related Disorders</i> , <b>2018</b> , 16, 530-536	2.6	10
233	Preclinical discovery and development of coleselam for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Discovery</i> , <b>2018</b> , 13, 1161-1167	6.2	5
232	Recovery of gut microbiota of healthy adults following antibiotic exposure. <i>Nature Microbiology</i> , <b>2018</b> , 3, 1255-1265	26.6	246
231	No changes in levels of bone formation and resorption markers following a broad-spectrum antibiotic course. <i>BMC Endocrine Disorders</i> , <b>2018</b> , 18, 60	3.3	3
230	Adaptive changes in pancreas post Roux-en-Y gastric bypass induced weight loss. <i>Diabetes/Metabolism Research and Reviews</i> , <b>2018</b> , 34, e3025	7.5	6

229	Bone Turnover Markers in Patients With Nonalcoholic Fatty Liver Disease and/or Type 2 Diabetes During Oral Glucose and Isoglycemic Intravenous Glucose. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2018</b> , 103, 2042-2049	5.6	10
228	SP426HYPOGLYCAEMIC EPISODES EVALUATED BY CONTINUOUS GLUCOSE MONITORING IN PATIENTS WITH TYPE 2 DIABETES AND DIALYSIS-DEPENDENT END-STAGE RENAL DISEASE RANDOMISED TO 12-WEEK LIRAGLUTIDE OR PLACEBO TREATMENT. <i>Nephrology Dialysis Transplantation</i> , <b>2018</b> , 33, i492-i492	4.3	
227	Cardiovascular safety and benefits of GLP-1 receptor agonists. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 351-363	4.1	25
226	Glucagon and Amino Acids Are Linked in a Mutual Feedback Cycle: The Liver- $\beta$ Cell Axis. <i>Diabetes</i> , <b>2017</b> , 66, 235-240	0.9	84
225	Efficacy and safety of fixed-ratio combination of insulin degludec and liraglutide (IDegLira) for the treatment of type 2 diabetes. <i>Expert Opinion on Drug Safety</i> , <b>2017</b> , 16, 387-396	4.1	11
224	Glucagon-like peptide-1 receptor agonists and risk of acute pancreatitis in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 906-908	6.7	59
223	Exenatide: pharmacokinetics, clinical use, and future directions. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 555-571	4	39
222	Short-acting glucagon-like peptide-1 receptor agonists as add-on to insulin therapy in type 1 diabetes: A review. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 915-925	6.7	8
221	Bile acid sequestrants for glycemic control in patients with type 2 diabetes: A systematic review with meta-analysis of randomized controlled trials. <i>Journal of Diabetes and Its Complications</i> , <b>2017</b> , 31, 918-927	3.2	46
220	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2017</b> , 136, 52-62	6.5	24
219	Effect of exercise combined with glucagon-like peptide-1 receptor agonist treatment on cardiac function: A randomized double-blind placebo-controlled clinical trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1040-1044	6.7	18
218	The effect of empagliflozin on oxidative nucleic acid modifications in patients with type 2 diabetes: protocol for a randomised, double-blinded, placebo-controlled trial. <i>BMJ Open</i> , <b>2017</b> , 7, e014728	3	9
217	Therapy: Liraglutide - preventing or postponing T2DM diagnosis?. <i>Nature Reviews Endocrinology</i> , <b>2017</b> , 13, 320-322	15.2	1
216	A sandwich ELISA for measurement of the primary glucagon-like peptide-1 metabolite. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2017</b> , 313, E284-E291	6	8
215	The Gut: A Key to the Pathogenesis of Type 2 Diabetes?. <i>Metabolic Syndrome and Related Disorders</i> , <b>2017</b> , 15, 259-262	2.6	8
214	Women with prior gestational diabetes mellitus and prediabetes are characterised by a decreased incretin effect. <i>Diabetologia</i> , <b>2017</b> , 60, 1344-1353	10.3	9
213	Mathematical Modelling of Glucose-Dependent Insulinotropic Polypeptide and Glucagon-like Peptide-1 following Ingestion of Glucose. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2017</b> , 121, 290-297	3.1	2
212	Postprandial Plasma Concentrations of ProANP in Patients with Type 2 Diabetes and Healthy Controls. <i>Clinical Chemistry</i> , <b>2017</b> , 63, 1040-1041	5.5	4

211	Evidence connecting old, new and neglected glucose-lowering drugs to bile acid-induced GLP-1 secretion: A review. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 1214-1222	6.7	12
210	Incidence and Prognosis of Psoriasis and Psoriatic Arthritis in Patients Undergoing Bariatric Surgery. <i>JAMA Surgery</i> , <b>2017</b> , 152, 344-349	5.4	51
209	Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide. <i>Clinical Pharmacokinetics</i> , <b>2017</b> , 56, 719-731	6.2	10
208	Effects of liraglutide on cardiovascular risk factors in patients with type 1 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 734-738	6.7	12
207	Current Therapies That Modify Glucagon Secretion: What Is the Therapeutic Effect of Such Modifications?. <i>Current Diabetes Reports</i> , <b>2017</b> , 17, 128	5.6	11
206	Improvement of Insulin Sensitivity after Lean Donor Feces in Metabolic Syndrome Is Driven by Baseline Intestinal Microbiota Composition. <i>Cell Metabolism</i> , <b>2017</b> , 26, 611-619.e6	24.6	440
205	Supportive and non-supportive interactions in families with a type 2 diabetes patient: an integrative review. <i>Diabetology and Metabolic Syndrome</i> , <b>2017</b> , 9, 57	5.6	36
204	MO019INCRETIN EFFECT IS REDUCED IN END-STAGE RENAL DISEASE. <i>Nephrology Dialysis Transplantation</i> , <b>2017</b> , 32, iii49-iii49	4.3	
203	Single-Dose Metformin Enhances Bile Acid-Induced Glucagon-Like Peptide-1 Secretion in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2017</b> , 102, 4153-4162	5.6	19
202	No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia. <i>Acta Psychiatrica Scandinavica</i> , <b>2017</b> , 136, 526-527	6.5	
201	Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production. <i>Cell Reports</i> , <b>2017</b> , 21, 1452-1460	10.6	18
200	Impaired beta cell sensitivity to incretins in type 2 diabetes is insufficiently compensated by higher incretin response. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2017</b> , 27, 1123-1129	4.5	12
199	Adult atopic dermatitis and the risk of type 2 diabetes. <i>Journal of Allergy and Clinical Immunology</i> , <b>2017</b> , 139, 1057-1059	11.5	19
198	Nonalcoholic Fatty Liver Disease Is Prevalent in Women With Prior Gestational Diabetes Mellitus and Independently Associated With Insulin Resistance and Waist Circumference. <i>Diabetes Care</i> , <b>2017</b> , 40, 109-116	14.6	33
197	Use of antibiotics in childhood and risk of Type 1 diabetes: a population-based case-control study. <i>Diabetic Medicine</i> , <b>2017</b> , 34, 272-277	3.5	25
196	Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 162-171	6.7	33
195	The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 189-199	6.7	15
194	Near-normalization of glycaemic control with glucagon-like peptide-1 receptor agonist treatment combined with exercise in patients with type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2017</b> , 19, 172-180	6.7	21

193	Clinical relevance of the bile acid receptor TGR5 in metabolism. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 224-233	18.1	77
192	Weight loss for overweight and obese individuals with gout: a systematic review of longitudinal studies. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 1870-1882	2.4	67
191	Safety and Efficacy of Liraglutide in Patients With Type 2 Diabetes and End-Stage Renal Disease: An Investigator-Initiated, Placebo-Controlled, Double-Blind, Parallel-Group, Randomized Trial. <i>Diabetes Care</i> , <b>2016</b> , 39, 206-13	14.6	34
190	Palaeolithic diet decreases fasting plasma leptin concentrations more than a diabetes diet in patients with type 2 diabetes: a randomised cross-over trial. <i>Cardiovascular Diabetology</i> , <b>2016</b> , 15, 80	8.7	61
189	Higher Endogenous Glucose Production During OGTT vs Isoglycemic Intravenous Glucose Infusion. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 4377-4384	5.6	8
188	Mechanism-Based Modeling of Gastric Emptying Rate and Gallbladder Emptying in Response to Caloric Intake. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , <b>2016</b> , 5, 692-700	4.5	9
187	Effects of glucose-dependent insulinotropic polypeptide on glucagon. <i>Cardiovascular Endocrinology</i> , <b>2016</b> , 5, 75-81		1
186	Disturbed postprandial glucose metabolism and gut hormone responses in non-diabetic patients with psoriasis. <i>British Journal of Dermatology</i> , <b>2016</b> , 175, 1085-1088	4	3
185	Cholecystokinin-Induced Gallbladder Emptying and Metformin Elicit Additive Glucagon-Like Peptide-1 Responses. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 2076-83	5.6	20
184	Postprandial Plasma Concentrations of Individual Bile Acids and FGF-19 in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2016</b> , 101, 3002-9	5.6	72
183	Risk stratification by endocrinologists of patients with type 2 diabetes in a Danish specialised outpatient clinic: a cross-sectional study. <i>BMC Health Services Research</i> , <b>2016</b> , 16, 124	2.9	10
182	Shared care management of patients with type 2 diabetes across the primary and secondary healthcare sectors: study protocol for a randomised controlled trial. <i>Trials</i> , <b>2016</b> , 17, 277	2.8	7
181	Effect of chenodeoxycholic acid and the bile acid sequestrant colesevelam on glucagon-like peptide-1 secretion. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 571-80	6.7	55
180	Evidence of Extrapancreatic Glucagon Secretion in Man. <i>Diabetes</i> , <b>2016</b> , 65, 585-97	0.9	102
179	Efficacy and safety of liraglutide for overweight adult patients with type 1 diabetes and insufficient glycaemic control (Lira-1): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 221-232	18.1	83
178	GLP-1 Restores Altered Insulin and Glucagon Secretion in Posttransplantation Diabetes. <i>Diabetes Care</i> , <b>2016</b> , 39, 617-24	14.6	31
177	Cephalic phase secretion of insulin and other enteropancreatic hormones in humans. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 310, G43-51	5.1	38
176	GLP-1 and Amylin in the Treatment of Obesity. <i>Current Diabetes Reports</i> , <b>2016</b> , 16, 1	5.6	35

175	Effects of glucagon-like peptide-1 on glucagon secretion in patients with non-alcoholic fatty liver disease. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 908-15	13.4	15
174	A comprehensive compartmental model of blood glucose regulation for healthy and type 2 diabetic subjects. <i>Medical and Biological Engineering and Computing</i> , <b>2016</b> , 54, 1383-98	3.1	12
173	Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion. <i>Journal of Diabetes Research</i> , <b>2016</b> , 2016, 8352957	3.9	25
172	Benefits and Harms of Sodium-Glucose Co-Transporter 2 Inhibitors in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , <b>2016</b> , 11, e0166125	3.7	126
171	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: a systematic review and meta-analysis. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 300-5	6.7	83
170	Involvement of glucagon-like peptide-1 in the glucose-lowering effect of metformin. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 955-61	6.7	42
169	Semimechanistic model describing gastric emptying and glucose absorption in healthy subjects and patients with type 2 diabetes. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 340-8	2.9	8
168	Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium-Glucose Cotransporter 2 Inhibitor Treatment. <i>Basic and Clinical Pharmacology and Toxicology</i> , <b>2016</b> , 118, 168-70	3.1	32
167	Effect of antibiotics on gut microbiota, glucose metabolism and body weight regulation: a review of the literature. <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 444-53	6.7	48
166	Diabetes and obesity treatment based on dual incretin receptor activation: <i>Mw</i> incretinsM <i>Diabetes, Obesity and Metabolism</i> , <b>2016</b> , 18, 847-54	6.7	34
165	Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. <i>Journal of Internal Medicine</i> , <b>2016</b> , 279, 485-93	10.8	32
164	Non-Insulin Parenteral Therapies <b>2016</b> , 455-470		
163	Oxyntomodulin Identified as a Marker of Type 2 Diabetes and Gastric Bypass Surgery by Mass-spectrometry Based Profiling of Human Plasma. <i>EBioMedicine</i> , <b>2016</b> , 7, 112-20	8.8	42
162	Involvement of steatosis-induced glucagon resistance in hyperglucagonaemia. <i>Medical Hypotheses</i> , <b>2016</b> , 86, 100-3	3.8	17
161	Vagotomy and subsequent development of diabetes - A nested case-control study. <i>Metabolism: Clinical and Experimental</i> , <b>2016</b> , 65, 954-60	12.7	4
160	The biology of glucagon and the consequences of hyperglucagonemia. <i>Biomarkers in Medicine</i> , <b>2016</b> , 10, 1141-1151	2.3	57
159	Species-specific action of (Pro3)GIP - a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors. <i>British Journal of Pharmacology</i> , <b>2016</b> , 173, 27-38	8.6	59
158	N-terminally and C-terminally truncated forms of glucose-dependent insulinotropic polypeptide are high-affinity competitive antagonists of the human GIP receptor. <i>British Journal of Pharmacology</i> , <b>2016</b> , 173, 826-38	8.6	55



157	Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial. <i>Journal of the European Academy of Dermatology and Venereology</i> , <b>2015</b> , 29, 555-9	4.6	23
156	Plasma YKL-40 during pregnancy and gestational diabetes mellitus. <i>Journal of Reproductive Immunology</i> , <b>2015</b> , 112, 68-72	4.2	5
155	Pancreatic polypeptide responses to isoglycemic oral and intravenous glucose in humans with and without intact vagal innervation. <i>Peptides</i> , <b>2015</b> , 71, 229-31	3.8	12
154	Postprandial prolactin suppression appears absent in antipsychotic-treated male patients. <i>Psychoneuroendocrinology</i> , <b>2015</b> , 60, 1-6	5	6
153	Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer. <i>Expert Opinion on Drug Safety</i> , <b>2015</b> , 14, 171-80	4.1	23
152	Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics/pharmacodynamics and clinical efficacy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2015</b> , 11, 1493-503	5.5	6
151	Effect of Roux-en-Y gastric bypass on the distribution and hormone expression of small-intestinal enteroendocrine cells in obese patients with type 2 diabetes. <i>Diabetologia</i> , <b>2015</b> , 58, 2254-8	10.3	83
150	Pancreatic Amylase and Lipase Plasma Concentrations Are Unaffected by Increments in Endogenous GLP-1 Levels Following Liquid Meal Tests. <i>Diabetes Care</i> , <b>2015</b> , 38, e71-2	14.6	10
149	Postprandial incretin and islet hormone responses and dipeptidyl-peptidase 4 enzymatic activity in patients with maturity onset diabetes of the young. <i>European Journal of Endocrinology</i> , <b>2015</b> , 173, 205-15	6.5	10
148	Fixed combination of insulin and a glucagon-like peptide-1 analog for the treatment of type 2 diabetes, exemplified by insulin degludec and liraglutide. <i>Expert Review of Clinical Pharmacology</i> , <b>2015</b> , 8, 273-82	3.8	1
147	Premature explantation of an EndoBarrier gastrointestinal liner because of sleeve invagination. <i>Endoscopy</i> , <b>2015</b> , 47 Suppl 1 UCTN, E275-6	3.4	3
146	Effect of Oxyntomodulin, Glucagon, GLP-1, and Combined Glucagon +GLP-1 Infusion on Food Intake, Appetite, and Resting Energy Expenditure. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 4541-52	5.6	51
145	Use of Antibiotics and Risk of Type 2 Diabetes: A Population-Based Case-Control Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 3633-40	5.6	85
144	Clearance of glucoregulatory peptide hormones during haemodialysis and haemodiafiltration in non-diabetic end-stage renal disease patients. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30, 513-20	4.3	11
143	Recovery of the incretin effect in type 2 diabetic patients after biliopancreatic diversion. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 1984-8	5.6	8
142	Transfer of liraglutide from blood to cerebrospinal fluid is minimal in patients with type 2 diabetes. <i>International Journal of Obesity</i> , <b>2015</b> , 39, 1651-4	5.5	33
141	Glucose-dependent insulinotropic polypeptide augments glucagon responses to hypoglycemia in type 1 diabetes. <i>Diabetes</i> , <b>2015</b> , 64, 72-8	0.9	49
140	Retinal vascular and structural dynamics during acute hyperglycaemia. <i>Acta Ophthalmologica</i> , <b>2015</b> , 93, 697-705	3.7	7

139	Impaired incretin effect is an early sign of glucose dysmetabolism in nondiabetic patients with psoriasis. <i>Journal of Internal Medicine</i> , <b>2015</b> , 278, 660-70	10.8	13
138	Influence of gastrointestinal factors on glucose metabolism in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1522-8	4	10
137	Effect of Antibiotics on Gut Microbiota, Gut Hormones and Glucose Metabolism. <i>PLoS ONE</i> , <b>2015</b> , 10, e0142352	3.7	61
136	Effects of sitagliptin on counter-regulatory and incretin hormones during acute hypoglycaemia in patients with type 1 diabetes: a randomized double-blind placebo-controlled crossover study. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 546-553	6.7	15
135	Efficacy and safety of the glucagon-like peptide-1 receptor agonist liraglutide added to insulin therapy in poorly regulated patients with type 1 diabetes--a protocol for a randomised, double-blind, placebo-controlled study: the Lira-1 study. <i>BMJ Open</i> , <b>2015</b> , 5, e007791	3	9
134	Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. <i>Diabetes Care</i> 2015;38:1858-1867. <i>Diabetes Care</i> , <b>2015</b> , 38, e215	14.6	4
133	The role of efferent cholinergic transmission for the insulinotropic and glucagonostatic effects of GLP-1. <i>American Journal of Physiology - Regulatory Integrative and Comparative Physiology</i> , <b>2015</b> , 309, R544-51	3.2	19
132	Patients with psoriasis are insulin resistant. <i>Journal of the American Academy of Dermatology</i> , <b>2015</b> , 72, 599-605	4.5	48
131	Sevelamer in a diabetologist's perspective: a phosphate-binding resin with glucose-lowering potential. <i>Diabetes, Obesity and Metabolism</i> , <b>2015</b> , 17, 116-20	6.7	10
130	Incretin effect and glucagon responses to oral and intravenous glucose in patients with maturity-onset diabetes of the young--type 2 and type 3. <i>Diabetes</i> , <b>2014</b> , 63, 2838-44	0.9	34
129	Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E418-26	5.6	57
128	Impact of oral vancomycin on gut microbiota, bile acid metabolism, and insulin sensitivity. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 824-31	13.4	353
127	Glucagon and type 2 diabetes: the return of the alpha cell. <i>Current Diabetes Reports</i> , <b>2014</b> , 14, 555	5.6	71
126	Postprandial gallbladder emptying in patients with type 2 diabetes: potential implications for bile-induced secretion of glucagon-like peptide 1. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 407-19	6.5	46
125	The design and discovery of lixisenatide for the treatment of type 2 diabetes mellitus. <i>Expert Opinion on Drug Discovery</i> , <b>2014</b> , 9, 1223-51	6.2	21
124	Glucagon responses to increasing oral loads of glucose and corresponding isoglycaemic intravenous glucose infusions in patients with type 2 diabetes and healthy individuals. <i>Diabetologia</i> , <b>2014</b> , 57, 1720-5	10.3	39
123	Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels?. <i>Diabetologia</i> , <b>2014</b> , 57, 1919-26	10.3	129
122	Unprecedented high insulin secretion in a healthy human subject after intravenous glucagon-like peptide-1: a case report. <i>BMC Research Notes</i> , <b>2014</b> , 7, 326	2.3	1

121	Postprandial responses of incretin and pancreatic hormones in non-diabetic patients with end-stage renal disease. <i>Nephrology Dialysis Transplantation</i> , <b>2014</b> , 29, 119-27	4.3	13
120	Elimination and degradation of glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with end-stage renal disease. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, 2457-66	5.6	19
119	Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. <i>Diabetes, Obesity and Metabolism</i> , <b>2014</b> , 16, 1155-64	6.7	69
118	Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial. <i>Diabetes Care</i> , <b>2014</b> , 37, 1797-805	14.6	56
117	Genetic variation in the two-pore domain potassium channel, TASK-1, may contribute to an atrial substrate for arrhythmogenesis. <i>Journal of Molecular and Cellular Cardiology</i> , <b>2014</b> , 67, 69-76	5.8	51
116	Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. <i>European Journal of Internal Medicine</i> , <b>2014</b> , 25, 407-14	3.9	101
115	Decreased plasma chemerin levels in women with gestational diabetes mellitus. <i>Diabetic Medicine</i> , <b>2014</b> , 31, 936-40	3.5	21
114	The effects of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: protocol for a systematic review with meta-analysis of randomised trials. <i>BMJ Open</i> , <b>2014</b> , 4, e005378	3	2
113	Dulaglutide: a novel once-weekly glucagon-like peptide-1 receptor agonist. <i>Clinical Investigation</i> , <b>2014</b> , 4, 729-743		1
112	Bile acid sequestrants in type 2 diabetes: potential effects on GLP1 secretion. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, R47-65	6.5	49
111	A 25-year-old woman with type 2 diabetes and liver disease. <i>Case Reports in Gastroenterology</i> , <b>2014</b> , 8, 398-403	1	1
110	Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2014</b> , 99, E2325-9	5.6	86
109	The authors reply. <i>Kidney International</i> , <b>2014</b> , 85, 212-3	9.9	
108	The use of double-balloon enteroscopy in retrieving mucosal biopsies from the entire human gastrointestinal tract. <i>Scandinavian Journal of Gastroenterology</i> , <b>2014</b> , 49, 1143-9	2.4	4
107	On the role of gallbladder emptying and incretin hormones for nutrient-mediated TSH suppression in patients with type 2 diabetes. <i>Endocrine Connections</i> , <b>2014</b> , 3, 193-9	3.5	2
106	Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol. <i>BMJ Open</i> , <b>2014</b> , 4, e004158	3	16
105	The impact of dipeptidyl peptidase 4 inhibition on incretin effect, glucose tolerance, and gastrointestinal-mediated glucose disposal in healthy subjects. <i>European Journal of Endocrinology</i> , <b>2014</b> , 171, 353-62	6.5	19
104	Effects of lixisenatide on elevated liver transaminases: systematic review with individual patient data meta-analysis of randomised controlled trials on patients with type 2 diabetes. <i>BMJ Open</i> , <b>2014</b> , 4, e005325	3	44

103	Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. <i>European Journal of Endocrinology</i> , <b>2014</b> , 170, 529-38	6.5	101
102	Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. <i>Nutrition, Metabolism and Cardiovascular Diseases</i> , <b>2014</b> , 24, 670-6	4.5	27
101	Improvement in psoriasis after treatment with the glucagon-like peptide-1 receptor agonist liraglutide. <i>Acta Diabetologica</i> , <b>2014</b> , 51, 147-50	3.9	28
100	Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. <i>Acta Diabetologica</i> , <b>2014</b> , 51, 567-75	3.9	22
99	Use of exenatide and liraglutide in Denmark: a drug utilization study. <i>European Journal of Clinical Pharmacology</i> , <b>2014</b> , 70, 205-14	2.8	9
98	Bile acid sequestrants: glucose-lowering mechanisms and efficacy in type 2 diabetes. <i>Current Diabetes Reports</i> , <b>2014</b> , 14, 482	5.6	33
97	Glucometabolic hormones and cardiovascular risk markers in antipsychotic-treated patients. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, e899-905	4.6	16
96	Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. <i>Diabetologia</i> , <b>2013</b> , 56, 965-72	10.3	167
95	Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes: systematic review and meta-analysis of clinical studies. <i>Diabetes Care</i> , <b>2013</b> , 36, 3346-52	14.6	101
94	Effect of the EndoBarrier Gastrointestinal Liner on obesity and type 2 diabetes: protocol for systematic review and meta-analysis of clinical studies. <i>BMJ Open</i> , <b>2013</b> , 3, e003417	3	17
93	Incretin and pancreatic hormone secretion in Caucasian non-diabetic carriers of the TCF7L2 rs7903146 risk T allele. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 91-5	6.7	20
92	GLP-1 agonists for type 2 diabetes: pharmacokinetic and toxicological considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 17-29	5.5	39
91	Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus. <i>Regulatory Peptides</i> , <b>2013</b> , 186, 104-7		13
90	The Role of Glucagon-like Receptor-1 Agonists in the Metabolic Syndrome <b>2013</b> , 165-183		
89	Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. <i>Diabetic Medicine</i> , <b>2013</b> , 30, 1214-8	3.5	47
88	Gastrointestinal factors contribute to glucometabolic disturbances in nondiabetic patients with end-stage renal disease. <i>Kidney International</i> , <b>2013</b> , 83, 915-23	9.9	24
87	Reduced postprandial GLP-1 responses in women with gestational diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2013</b> , 15, 713-20	6.7	19
86	Safety and efficacy of liraglutide in patients with type 2 diabetes and end-stage renal disease: protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded, parallel intervention study. <i>BMJ Open</i> , <b>2013</b> , 3,	3	11

85	The effect of a glucagon-like peptide-1 receptor agonist on glucose tolerance in women with previous gestational diabetes mellitus: protocol for an investigator-initiated, randomised, placebo-controlled, double-blinded, parallel intervention trial. <i>BMJ Open</i> , <b>2013</b> , 3, e003834	3	7
84	Sustained weight loss after treatment with a glucagon-like peptide-1 receptor agonist in an obese patient with schizophrenia and type 2 diabetes. <i>American Journal of Psychiatry</i> , <b>2013</b> , 170, 681-2	11.9	17
83	Postprandial gut hormone responses and glucose metabolism in cholecystectomized patients. <i>American Journal of Physiology - Renal Physiology</i> , <b>2013</b> , 304, G413-9	5.1	29
82	The effect of exogenous GLP-1 on food intake is lost in male truncally vagotomized subjects with pyloroplasty. <i>American Journal of Physiology - Renal Physiology</i> , <b>2013</b> , 304, G1117-27	5.1	114
81	Mechanism of metabolic advantages after bariatric surgery: it's all gastrointestinal factors versus it's all food restriction. <i>Diabetes Care</i> , <b>2013</b> , 36 Suppl 2, S287-91	14.6	55
80	Characterisation of oral and i.v. glucose handling in truncally vagotomised subjects with pyloroplasty. <i>European Journal of Endocrinology</i> , <b>2013</b> , 169, 187-201	6.5	42
79	Cardiovascular effects of alpha-linolenic acid--a possible role of glucagon-like peptide-1. <i>Experimental Biology and Medicine</i> , <b>2013</b> , 238, 1116-7	3.7	
78	Increased expression of glucagon-like peptide-1 receptors in psoriasis plaques. <i>Experimental Dermatology</i> , <b>2013</b> , 22, 150-2	4	17
77	TASK-1 potassium channel mutations in atrial fibrillation. <i>European Heart Journal</i> , <b>2013</b> , 34, 3411-3411	9.5	3
76	Lixisenatide for the treatment of type 2 diabetes. <i>Drugs of Today</i> , <b>2013</b> , 49, 537	2.5	16
75	Mechanisms of the incretin effect in subjects with normal glucose tolerance and patients with type 2 diabetes. <i>PLoS ONE</i> , <b>2013</b> , 8, e73154	3.7	29
74	Glucagon and the gut hormones GLP-1 and oxyntomodulin increase resting energy expenditure in man. <i>Regulatory Peptides</i> , <b>2012</b> , 177, S15-S16		2
73	Current evidence for a role of GLP-1 in Roux-en-Y gastric bypass-induced remission of type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 291-8	6.7	34
72	Impaired incretin effect and fasting hyperglucagonaemia characterizing type 2 diabetic subjects are early signs of dysmetabolism in obesity. <i>Diabetes, Obesity and Metabolism</i> , <b>2012</b> , 14, 500-10	6.7	117
71	Electroretinography in healthy subjects in relation to systemic glucocorticoid intake. <i>Documenta Ophthalmologica</i> , <b>2012</b> , 124, 49-57	2.2	3
70	The unobtainable placebo: control of independent clinical research by industry?. <i>Lancet, The</i> , <b>2012</b> , 379, 30	40	10
69	Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. <i>BMJ, The</i> , <b>2012</b> , 344, d7771	5.9	575
68	Glucagon-like peptide-1 analogs against antipsychotic-induced weight gain: potential physiological benefits. <i>BMC Medicine</i> , <b>2012</b> , 10, 92	11.4	19

67	Effect of bile acid sequestrants on glycaemic control: protocol for a systematic review with meta-analysis of randomised controlled trials. <i>BMJ Open</i> , <b>2012</b> , 2,	3	6
66	Comment on: Gębek et al. Glucose-dependent insulinotropic polypeptide reduces fat-specific expression and activity of 11 $\beta$ -hydroxysteroid dehydrogenase type 1 and inhibits release of free fatty acids. <i>Diabetes</i> 2012;61:292-300. <i>Diabetes</i> , <b>2012</b> , 61, e12	0.9	1
65	Worry vs. knowledge about treatment-associated hypoglycaemia and weight gain in type 2 diabetic patients on metformin and/or sulphonylurea. <i>Current Medical Research and Opinion</i> , <b>2012</b> , 28, 731-6	2.5	12
64	Impaired incretin-induced amplification of insulin secretion after glucose homeostatic dysregulation in healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2012</b> , 97, 1363-70	5.6	53
63	Letter by Knop regarding article, "Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the investigation of lipid level management to understand its impact in atherosclerotic events (ILLUMINATE) trial". <i>Circulation</i> , <b>2012</b> , 125, e428	16.7	
62	Increased levels of YKL-40 and interleukin 6 in patients with chronic pancreatitis and secondary diabetes. <i>Pancreas</i> , <b>2012</b> , 41, 1316-8	2.6	10
61	Emerging GLP-1 receptor agonists. <i>Expert Opinion on Emerging Drugs</i> , <b>2011</b> , 16, 607-18	3.7	20
60	2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, E1409-17	5.6	201
59	Gastric bypass surgery: improving psoriasis through a GLP-1-dependent mechanism?. <i>Medical Hypotheses</i> , <b>2011</b> , 77, 1098-101	3.8	30
58	First case report associating chronic pancreatitis and Ehlers-Danlos syndrome. <i>Pancreas</i> , <b>2011</b> , 40, 157-9	2.6	1
57	Glucagon antagonism as a potential therapeutic target in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13, 965-71	6.7	99
56	Regulation of glucagon secretion by incretins. <i>Diabetes, Obesity and Metabolism</i> , <b>2011</b> , 13 Suppl 1, 89-94	6.7	106
55	Lixisenatide for type 2 diabetes mellitus. <i>Expert Opinion on Investigational Drugs</i> , <b>2011</b> , 20, 549-57	5.9	64
54	Gastric emptying of orally administered glucose solutions and incretin hormone responses are unaffected by laparoscopic adjustable gastric banding. <i>Obesity Surgery</i> , <b>2011</b> , 21, 625-32	3.7	24
53	Inhibition de la sécrétion du glucagon par les agonistes du GLP-1 et les inhibiteurs de la DPP-4. <i>Medecine Des Maladies Metaboliques</i> , <b>2011</b> , 5, 139-145	0.1	1
52	Comment on: Chen et al. utilizing the second-meal effect in type 2 diabetes: practical use of a soya-yogurt snack. <i>Diabetes Care</i> 2010;33:2552-554. <i>Diabetes Care</i> , <b>2011</b> , 34, e44; author reply e45	14.6	2
51	The GetGoal clinical trial program of lixisenatide, a once-daily GLP-1 receptor agonist. <i>Expert Review of Endocrinology and Metabolism</i> , <b>2011</b> , 6, 513-525	4.1	5
50	Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. <i>Diabetes Care</i> , <b>2011</b> , 34 Suppl 2, S251-7	14.6	185

49	Increased postprandial GIP and glucagon responses, but unaltered GLP-1 response after intervention with steroid hormone, relative physical inactivity, and high-calorie diet in healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 447-53	5.6	124
48	Glucose-dependent insulintropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. <i>Diabetes</i> , <b>2011</b> , 60, 3103-9	0.9	208
47	Impaired regulation of the incretin effect in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2011</b> , 96, 737-45	5.6	157
46	The separate and combined impact of the intestinal hormones, GIP, GLP-1, and GLP-2, on glucagon secretion in type 2 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2011</b> , 300, E1038-46	6	118
45	Therapy for obesity based on gastrointestinal hormones. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 339-47	3.6	8
44	The alpha-cell as target for type 2 diabetes therapy. <i>Review of Diabetic Studies</i> , <b>2011</b> , 8, 369-81	3.6	42
43	Twelve weeks treatment with the DPP-4 inhibitor, sitagliptin, prevents degradation of peptide YY and improves glucose and non-glucose induced insulin secretion in patients with type 2 diabetes mellitus. <i>Diabetes, Obesity and Metabolism</i> , <b>2010</b> , 12, 323-33	6.7	95
42	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes &ndash; a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , Volume 3, 155-163	3.4	16
41	The glucagonostatic and insulintropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. <i>Diabetes</i> , <b>2010</b> , 59, 1765-70	0.9	194
40	Comment on: Villareal et al. (2009) TCF7L2 variant rs7903146 affects the risk of type 2 diabetes by modulating incretin action. <i>Diabetes</i> ;59:479-485. <i>Diabetes</i> , <b>2010</b> , 59, e4; author reply e5-6	0.9	3
39	Reduced glucose tolerance and insulin resistance induced by steroid treatment, relative physical inactivity, and high-calorie diet impairs the incretin effect in healthy subjects. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 3309-17	5.6	77
38	Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with type 1 diabetes. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2010</b> , 298, E832-7	6	53
37	Bile-induced secretion of glucagon-like peptide-1: pathophysiological implications in type 2 diabetes?. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2010</b> , 299, E10-3	6	48
36	Do the actions of glucagon-like peptide-1 on gastric emptying, appetite, and food intake involve release of amylin in humans?. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2010</b> , 95, 2367-75	5.6	27
35	Increased postprandial response of glucagon-like peptide-2 in patients with chronic pancreatitis and pancreatic exocrine insufficiency. <i>Pancreatology</i> , <b>2010</b> , 10, 201-7	3.8	7
34	Glucagon-like peptide-2, but not glucose-dependent insulintropic polypeptide, stimulates glucagon release in patients with type 1 diabetes. <i>Regulatory Peptides</i> , <b>2010</b> , 163, 96-101		17
33	Incretin-based therapy and type 2 diabetes. <i>Vitamins and Hormones</i> , <b>2010</b> , 84, 389-413	2.5	18
32	Once-weekly GLP-1 agonists: How do they differ from exenatide and liraglutide?. <i>Current Diabetes Reports</i> , <b>2010</b> , 10, 124-32	5.6	39

31	Glucagon suppression during OGTT worsens while suppression during IVGTT sustains alongside development of glucose intolerance in patients with chronic pancreatitis. <i>Regulatory Peptides</i> , <b>2010</b> , 164, 144-50		23
30	Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes - a review. <i>Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy</i> , <b>2010</b> , 3, 155-63	3.4	10
29	Incretin hormones and beta cell function in chronic pancreatitis. <i>Danish Medical Bulletin</i> , <b>2010</b> , 57, B4163		8
28	Incretin-based therapy of type 2 diabetes mellitus. <i>Current Protein and Peptide Science</i> , <b>2009</b> , 10, 46-55	2.8	37
27	Preserved inhibitory potency of GLP-1 on glucagon secretion in type 2 diabetes mellitus. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 4679-87	5.6	82
26	KATP channel closure ameliorates the impaired insulinotropic effect of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 94, 603-8	5.6	44
25	Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2009</b> , 52, 199-207	10.3	296
24	Resolution of type 2 diabetes following gastric bypass surgery: involvement of gut-derived glucagon and glucagonotropic signalling?. <i>Diabetologia</i> , <b>2009</b> , 52, 2270-2276	10.3	63
23	Treatment of type 2 diabetes with glucagon-like peptide-1 receptor agonists. <i>International Journal of Clinical Practice</i> , <b>2009</b> , 63, 1154-60	2.9	35
22	The spectrum of antidiabetic actions of GLP-1 in patients with diabetes. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , <b>2009</b> , 23, 453-62	6.5	19
21	Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2009</b> , 12, 503-13		26
20	Four weeks of near-normalization of blood glucose has no effect on postprandial GLP-1 and GIP secretion, but augments pancreatic B-cell responsiveness to a meal in patients with Type 2 diabetes. <i>Diabetic Medicine</i> , <b>2008</b> , 25, 1268-75	3.5	37
19	Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). <i>American Heart Journal</i> , <b>2008</b> , 155, 26-32, 32.e1-6	4.9	146
18	Long-acting GLP-1 analogs for the treatment of type 2 diabetes mellitus. <i>BioDrugs</i> , <b>2008</b> , 22, 251-7	7.9	18
17	Response to Comment on: Knop et al. (2007) Reduced Incretin Effect in Type 2 Diabetes: Cause or Consequence of the Diabetic State? <i>Diabetes</i> 56:1951-1959. <i>Diabetes</i> , <b>2008</b> , 57, e2-e3	0.9	2
16	Near normalisation of blood glucose improves the potentiating effect of GLP-1 on glucose-induced insulin secretion in patients with type 2 diabetes. <i>Diabetologia</i> , <b>2008</b> , 51, 632-40	10.3	71
15	25th Scientific Meeting of the AngloDanishDutch Diabetes Group. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , <b>2008</b> , 25, 17-17		
14	Glucagon-like Peptides and Insulin Sensitivity <b>2008</b> , 233-254		



13	Replacing SUs with incretin-based therapies for type 2 diabetes mellitus: challenges and feasibility. <i>IDrugs: the Investigational Drugs Journal</i> , <b>2008</b> , 11, 497-501		4
12	Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?. <i>Diabetes</i> , <b>2007</b> , 56, 1951-9	0.9	251
11	Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in type 2 diabetes mellitus. <i>Diabetologia</i> , <b>2007</b> , 50, 797-805	10.3	137
10	Review: DPP IV inhibitors - current evidence and future directions. <i>British Journal of Diabetes and Vascular Disease</i> , <b>2007</b> , 7, 69-74		11
9	Increased postprandial responses of GLP-1 and GIP in patients with chronic pancreatitis and steatorrhea following pancreatic enzyme substitution. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , <b>2007</b> , 292, E324-30	6	71
8	The insulinotropic effect of GIP is impaired in patients with chronic pancreatitis and secondary diabetes mellitus as compared to patients with chronic pancreatitis and normal glucose tolerance. <i>Regulatory Peptides</i> , <b>2007</b> , 144, 123-30		46
7	The Nkx6.1 homeodomain transcription factor suppresses glucagon expression and regulates glucose-stimulated insulin secretion in islet beta cells. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2005</b> , 102, 7297-302	11.5	129
6	Self-expanding metal stents for colonic obstruction: experiences from 104 procedures in a single center. <i>Diseases of the Colon and Rectum</i> , <b>2004</b> , 47, 444-50	3.1	121
5	Delayed ischemic cecal perforation despite optimal decompression after placement of a self-expanding metal stent: report of a case. <i>Diseases of the Colon and Rectum</i> , <b>2004</b> , 47, 1970-3	3.1	4
4	Small-bowel hemangiosarcoma and capsule endoscopy. <i>Endoscopy</i> , <b>2003</b> , 35, 637	3.4	11
3	No hypoglycemia after subcutaneous administration of glucagon-like peptide-1 in lean type 2 diabetic patients and in patients with diabetes secondary to chronic pancreatitis. <i>Diabetes Care</i> , <b>2003</b> , 26, 2581-7	14.6	35
2	The pathophysiology of diabetes involves a defective amplification of the late-phase insulin response to glucose by glucose-dependent insulinotropic polypeptide-regardless of etiology and phenotype. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2003</b> , 88, 4897-903	5.6	175
1	Arginine-vasopressin mediates counter-regulatory glucagon release and is diminished in type 1 diabetes		1